Occam Recruits David Moller as Chief Scientific Officer of Variant Bio
Variant Bio, a genomics-driven drug discovery company backed by Lux Capital, General Catalyst, Alta Partners, SoftBank, and Casdin Capital, announced David Moller, MD as Chief Scientific Officer.
In Moller, Variant captures a broadly gauged and versatile drug discovery and development leader with over two decades of experience presiding over R&D in both big pharma and biotech, including Eli Lilly and Merck. He brings with him a deep understanding of and facility for transmuting complex genetic insights into innovative therapeutic programs, a knowledge that will doubtlessly enable Variant to deliver on its substantial potential as a transformative genomics-based drug discovery and development organization.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.